{"title":"勃林格殷格翰:对糖尿病的新承诺","authors":"","doi":"10.1002/fps.76","DOIUrl":null,"url":null,"abstract":"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its recent strategic alliance with Eli Lilly & Co to develop new treatments for diabetes, a new therapeutic area for the company.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 1","pages":"17-18"},"PeriodicalIF":0.0000,"publicationDate":"2011-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.76","citationCount":"0","resultStr":"{\"title\":\"Boehringer Ingelheim: a new commitment to diabetes\",\"authors\":\"\",\"doi\":\"10.1002/fps.76\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its recent strategic alliance with Eli Lilly & Co to develop new treatments for diabetes, a new therapeutic area for the company.</b></p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"12 1\",\"pages\":\"17-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.76\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.76\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.76","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Boehringer Ingelheim: a new commitment to diabetes
This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its recent strategic alliance with Eli Lilly & Co to develop new treatments for diabetes, a new therapeutic area for the company.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
